Roche on Tuesday night inadvertently disclosed positive results from a closely watched lung cancer drug study, showing the mmunotherapy drug tiragolumab, when taken with the commonly used antibody medicine Tecentriq, increased overall survival time for patients, The Financial Times’ Hannah Kuchler reports. Previous data from the same trial had shown that researchers missed another goal of showing a statistically significant difference in the growth of tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- Arcus to ‘trade with strength’ after leaked Roche data looked ‘good,’ says BofA
- Genentech provides update on SKYSCRAPER-01 study
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron upgraded to Buy at Canaccord after high dose EYLEA approved